Skip to content

Study the effect of Sundari Jeevak syrup in Kashtartava (Primary dysmenorrhea)

An open label clinical trial to evaluate the efficacy of Sundari Jeevak syrup in the management of Kashtartava (Primary dysmenorrhea)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/01/022673
Enrollment
50
Registered
2020-01-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

Intervention1: Sundari Jeevak Syrup: Sundari Jeevak syrup 20 ml before meal thrice a day orallywill be given 14 days after menstruation till the commencement of next cycle for two consecutive cycle. C

Sponsors

Multani Pharmaceuticals Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Females suffering from primary dysmenorrhea more than 3 consecutive cycles. 2. Female presenting primary dysmenorrhea with or without any of the following symptoms associated with- Any kind of pain like headache, backache, abdominal pain, body ache, Nausea and vomiting, Weakness. 3. Psychological symptoms- like anxiety, stress, depression, irritability, restlessness. 4. Willing to participate in the trial. 5. Readiness to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients having congenital anomalies, patient is suffering from acute infections, cervical stenosis etc. 2. Patients with chronic illness, patient using an intrauterine contraceptive device, and patient with menorrhagia or any uterine pathology (fibroid, adenomyosis, endometriosis etc.) will be excluded from the study. 3. Lactating female. 4. Individuals participating in any other clinical trial.

Design outcomes

Primary

MeasureTime frame
Changes pain (Primary dysmenorrhea).Timepoint: 90 days

Secondary

MeasureTime frame
Changes in associated symptomsTimepoint: 90 days

Countries

India

Contacts

Public ContactVd Hetal H Dave

Multani Pharmaceuticals Ltd.

dr.hstiwari@gmail.com9654350714

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026